Shun Yamamoto

Department Of Head And Neck
Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Clinical role of anti-PD-1 immunotherapies in esophageal cancer.

Clinical role of anti-PD-1 immunotherapies in esophageal cancer.

Journal: Expert review of gastroenterology & hepatology

Published: March 17, 2026

ISDE guidelines on the management of cT2N0 esophageal cancer.

ISDE guidelines on the management of cT2N0 esophageal cancer.

Journal: Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus

Published: January 23, 2026

FOLFOX plus nivolumab combination therapy for cisplatin-unfit patients with untreated advanced esophageal squamous cell carcinoma.

FOLFOX plus nivolumab combination therapy for cisplatin-unfit patients with untreated advanced esophageal squamous cell carcinoma.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: December 20, 2025

Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancer.

Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancer.

Journal: Future oncology (London, England)

Published: December 17, 2025

Impact of Neoadjuvant Docetaxel, Cisplatin, and 5-Fluorouracil Therapy on Synchronous Early-Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer.

Impact of Neoadjuvant Docetaxel, Cisplatin, and 5-Fluorouracil Therapy on Synchronous Early-Stage Oropharyngeal/Hypopharyngeal Cancer in Patients With Esophageal Cancer.

Journal: Head & neck

Published: November 04, 2025

Safety and short-term efficacy of neoadjuvant FLOT therapy in cisplatin-unfit patients with resectable esophageal squamous cell carcinoma.

Safety and short-term efficacy of neoadjuvant FLOT therapy in cisplatin-unfit patients with resectable esophageal squamous cell carcinoma.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: July 25, 2025

Real-world comparison between neoadjuvant FLOT therapy and DCF therapy for resectable esophagogastric junction adenocarcinoma.

Real-world comparison between neoadjuvant FLOT therapy and DCF therapy for resectable esophagogastric junction adenocarcinoma.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: July 15, 2025

Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma.

Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma.

Journal: Future oncology (London, England)

Published: April 21, 2025

Investigating the Synergistic Effects of Pembrolizumab and Chemotherapy in Gastric and Gastroesophageal Junction Cancer.

Investigating the Synergistic Effects of Pembrolizumab and Chemotherapy in Gastric and Gastroesophageal Junction Cancer.

Journal: Journal of gastric cancer

Published: March 13, 2025

The safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma.

The safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: March 02, 2025

Comprehensive registry of esophageal cancer in Japan, 2016.

Comprehensive registry of esophageal cancer in Japan, 2016.

Journal: Esophagus : official journal of the Japan Esophageal Society

Published: February 25, 2025

Correlation Between Histopathological Response of Esophageal Squamous Cell Carcinoma to Neoadjuvant DCF Therapy and the Clinical Efficacy of Palliative Chemotherapy for Recurrence.

Correlation Between Histopathological Response of Esophageal Squamous Cell Carcinoma to Neoadjuvant DCF Therapy and the Clinical Efficacy of Palliative Chemotherapy for Recurrence.

Journal: Journal of gastrointestinal cancer

Published: February 03, 2025

Showing 1-12 of 70

Last Updated: 09/26/2026